- absolute lymphocyte count <500/mm3 and absolute neutrophil count of <1000/mm3 and hemoglobin 8gm/dl or less - severe hepatic or renal impairment - live vaccine within 3 months prior to first dose of the drug - pregnancy - lactation - current malignancy or history of malignancies over the previous 5 years and/or history of malignancies in first degree relatives - transaminases values 5-fold higher than the upper normal limit - proven evidence of concomitant bacterial infections - clinical evidences suggestive of pulmonary tuberculosis, or past history and/or history of contact with tb patient - known hypersensitivity to baricitinib - those who have received tocilizumab previously

- absolute lymphocyte count <500/mm3 and absolute neutrophil count of <1000/mm3 and hemoglobin 8gm/dl or less - severe hepatic or renal impairment - live vaccine within 3 months prior to first dose of the drug - pregnancy - lactation - current malignancy or history of malignancies over the previous 5 years and/or history of malignancies in first degree relatives - transaminases values 5-fold higher than the upper normal limit - proven evidence of concomitant bacterial infections - clinical evidences suggestive of pulmonary tuberculosis, or past history and/or history of contact with tb patient - known hypersensitivity to baricitinib - those who have received tocilizumab previously